Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Document:USA 21 CFR Part 54 09-Apr-2025

From GxPlex

Revision as of 20:07, 27 June 2026 by Gxplex admin (talk | contribs) (1 revision imported)
Jump to: navigation, search


Document information
Reference USA 21 CFR Part 54 09-Apr-2025
Validity area USA
Scope(s) G
Document name 21 CFR Part 54
Version / Revision 09-Apr-2025
Status Current
Document type Legal act
Language(s) EN
Description Title 21 —Food and Drugs

Chapter I —Food and Drug Administration, Department of Health and Human Services Subchapter A—General Part 54 Financial Disclosure by Clinical Investigators https://www.ecfr.gov/current/title-21

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


References

Reference Scope Document part Language Preview
Reference:USA 21 CFR Part 54 09-Apr-2025 § 54.1-001 G § 54.1 EN § 54.1 Purpose. (a) The Food and Drug Administration (FDA) evaluates clinical studies submitted in marketing applications, required by law, for new human drugs and biological products and marketing ...
Reference:USA 21 CFR Part 54 09-Apr-2025 § 54.4 list of investigators G § 54.4

list of investigators || EN || § 54.4 Certification and disclosure requirements. For purposes of this part, an applicant must submit a list of all clinical investigators who conducted covered clinical studies to determine whether ...

Reference:USA 21 CFR Part 54 09-Apr-2025 § 54.4 disclosure G § 54.4

disclosure || EN || § 54.4 Certification and disclosure requirements. […] Clinical investigators subject to investigational new drug or investigational device exemption regulations must provide the sponsor of the study ...

Reference:USA 21 CFR Part 54 09-Apr-2025 § 54.1-002 G § 54.1 EN § 54.1 Purpose. (a) The Food and Drug Administration (FDA) evaluates clinical studies submitted in marketing applications, required by law, for new human drugs and biological products and marketing ...
Reference:USA 21 CFR Part 54 09-Apr-2025 § 54.6 G § 54.6 EN § 54.6 Recordkeeping and record retention. (a) Financial records of clinical investigators to be retained. An applicant who has submitted a marketing application containing covered clinical studies ...